Canaccord upgraded Mayne Pharma to Buy from Hold with a price target of A$6.69, up from A$3.80, after the company released its first half results. Positive trends across all segments are continuing and new management is well proving its ability to execute and to restore investor confidence in the longer-term sustainable growth story, the analyst tells investors.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
